Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01032-08PMID 19075052PMCID PMC2650549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

  2007cited by this paper
• Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability

  2007cited by this paper
• New animal models for hepatitis C viral infection and pathogenesis studies.

  2007cited by this paper
• Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.

  2006cited by this paper
• The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture*

  2006cited by this paper
• 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results

  2006influential reference
• Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

  2005cited by this paper
• Challenges and successes in developing new therapies for hepatitis C

  2005cited by this paper
• HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis.

  2004cited by this paper
• Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

  2004influential reference
• A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties

  2004influential reference
• Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

  2004cited by this paper
• Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

  2003influential reference
• Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs*

  2003cited by this paper
• Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase

  2003cited by this paper
• Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

  2003cited by this paper
• Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

  2003cited by this paper
• Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase*

  2002cited by this paper
• Studies of Hepatitis C Virus in Chimpanzees and Their Importance for Vaccine Development

  2001cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998influential reference
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Interferon Alfa-2b Alone or in Combination with Ribavin as Intial Treatment for Chronic Hepatitis C

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

  1989cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Rhinovirus triggers distinct host responses through differential engagement of epithelial innate immune signaling

  2026cites this paper
• NS5-targeting nucleoside analogs inhibit dengue virus and other flaviviruses.

  2026cites this paper
• MK-0608 inhibits in vitro and in vivo RNA replication of infectious pancreatic necrosis virus.

  2024cites this paper
• Adjusting susceptibilities of C57BL/6 mice to orthoflaviviruses for evaluation of antiviral drugs by altering the levels of interferon alpha/beta receptor function.

  2024cites this paper
• Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2.

  2024cites this paper
• Competing interests during the key N-glycosylation of 6-chloro-7-deaza-7-iodopurine for the synthesis of 7-deaza-2′-methyladenosine using Vorbrüggen conditions

  2023cites this paper
• Curing Hepatitis C with Direct‐Acting Antiviral Therapy

  2021cites this paper
• Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections

  2021cites this paper
• A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

  2020cites this paper
• Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitors

  2019cites this paper
• Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.

  2019cites this paper
• Synthesis and Anti‐HIV Activity of Guanine Modified Fluorinated Acyclic Nucleoside Phosphonate Derivatives

  2019cites this paper
• Characterization of functional determinants in the C-terminal part of hepatitis C virus E1 glycoprotein ectodomain

  2019cites this paper
• Current Progress and Challenges in the Development of a Hepatitis C Virus Vaccine

  2019cites this paper
• A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea

  2018cites this paper
• Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.

  2018cites this paper
• Nucleosides for the treatment of respiratory RNA virus infections

  2018cites this paper
• Animal Models to Study Hepatitis C Virus Infection

  2018cites this paper
• Development of a New Structural Class of Broadly Acting HCV Non‐Nucleoside Inhibitors Leading to the Discovery of MK‐8876

  2017cites this paper
• Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates.

  2017cites this paper
• The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis

  2017cites this paper
• Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor

  2017cites this paper
• Pyrrolo[2,3‐d]pyrimidine (7‐deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

  2017cites this paper
• Identification of drug resistance and immune‐driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine

  2017cites this paper
• Infection and propagation of hepatitis C virus in human CD4⁺ and CD8⁺ T lymphocytes in vitro

  2017cites this paper
• HCV Drug Resistance

  2017cites this paper
• Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.

  2016cites this paper
• Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics.

  2016cites this paper
• Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

  2016cites this paper
• Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.

  2016cites this paper
• Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance

  2016cites this paper
• Discovery of potent macrocyclic HCV NS5A inhibitors.

  2016cites this paper
• Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus.

  2016cites this paper
• Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

  2016cites this paper
• Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.

  2016cites this paper
• Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

  2016cites this paper
• My Cousin, My Enemy: quasispecies suppression of drug resistance

  2016cites this paper
• Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

  2016cites this paper
• Nucleoside Inhibitors of Tick-Borne Encephalitis Virus

  2015cites this paper
• Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus

  2015cites this paper
• Development of novel model systems to assess replication of patient derived hepatitis C virus in tissue culture

  2015cites this paper
• Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct‐acting antiviral

  2015cites this paper
• Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver artificial primary microrna mimics

  2015cites this paper
• Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections

  2014cites this paper
• Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients.

  2014cites this paper
• Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent C-Nucleoside Monophosphate Prodrug

  2014cites this paper
• Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus

  2014cites this paper
• T‐cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon‐free antiviral regimen in a chimpanzee

  2014cites this paper
• Recent highlights in the synthesis of anti-HCV ribonucleosides.

  2014cites this paper
• Direct-acting antiviral agents and the path to interferon independence.

  2014cites this paper
• Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology

  2014cites this paper
• Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

  2014cites this paper
• Inhibition of Hepatitis C Virus Replication by GS-6620 , A Potent C-Nucleoside 1 Monophosphate Prodrug 2 3 Running Title : In Vitro Pharmacology of GS-6620 4 5

  2014cites this paper
• Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design.

  2013influential citation
• The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.

  2013cites this paper
• Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A

  2013cites this paper
• Caractérisation fonctionnelle des interactions virus-kinases lors de l'entrée cellulaire du virus de l'hépatite C

  2013cites this paper
• RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.

  2013cites this paper
• Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome.

  2013cites this paper
• Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity

  2013cites this paper
• MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

  2012cites this paper
• Synthesis and Antiviral Properties of Novel Tetracyclic Nucleoside Inhibitors of Hepatitis C NS5B Polymerase

  2012cites this paper
• Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.

  2012cites this paper
• Human mitochondrial RNA polymerase: structure-function, mechanism and inhibition.

  2012cites this paper
• Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes.

  2012cites this paper
• Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides

  2012cites this paper
• Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.

  2012cites this paper
• New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

  2012cites this paper
• Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.

  2012cites this paper
• Animal models for the study of hepatitis C virus infection and related liver disease.

  2012cites this paper
• Dengue Drug Discovery

  2011cites this paper
• Nucleotide Prodrugs for HCV Therapy

  2011cites this paper
• Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.

  2011cites this paper
• Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity

  2011cites this paper
• Therapeutic opportunities in dengue infection

  2011cites this paper
• Nucleic Acids as Biomolecular Probes: Synthesis, Substrate, and Antiviral Properties

  2011cites this paper
• Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice.

  2011cites this paper
• New treatments for chronic hepatitis C

  2010cites this paper
• Inhibition of Dengue Virus RNA Synthesis by an Adenosine Nucleoside

  2010cites this paper
• Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop

  2010cites this paper
• New NS5B polymerase inhibitors for hepatitis C

  2010cites this paper
• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C

  2010cites this paper
• Strategies for development of Dengue virus inhibitors.

  2010cites this paper
• HCV NS5B polymerase inhibitors.

  2010cites this paper
• An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model

  2010cites this paper
• An Assessment of the Use of Chimpanzees in Hepatitis C Research Past , Present and Future : 1 . Validity of the Chimpanzee Model

  2010cites this paper
• Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents

  2010influential citation
• Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B

  2010cites this paper
• Antiviral Efficacy upon Administration of a HepDirect Prodrug of 2′-C-Methylcytidine to Hepatitis C Virus-Infected Chimpanzees

  2009cites this paper
• Chapter 20 Progress towards the Discovery and Development of Specifically Targeted Inhibitors of Hepatitis C Virus

  2009cites this paper
• Overview of known non-human primate pathogens with potential to affect colonies used for toxicity testing

  2009cites this paper
• Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.

  2009cites this paper
• Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.

  2009cites this paper
• Hepatitis C therapy—the future looks bright

  2009cites this paper
• HCV NS5B polymerase inhibitors.

  2009cites this paper
• Experimental models for hepatitis C viral infection

  2009cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Finally Sofosbuvir: an Oral Anti-hcv Drug with Wide Performance Capability

  year unknowncites this paper
• Guidelines for the Treatment of Psoriatic Arthritis with Biologics the British Society for Rheumatology 2012 Guidelines for the Treatment of Psoriatic Arthritis with Biologics

  year unknowncites this paper